Generation of Polyclonal Antibodies Against Recombinant Human Glucocerebrosidase Produced in Escherichia coli
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Deficiency of the lysosomal glucocerebrosidase (GCR) enzyme results in Gaucher’s disease, the most common inherited storage disorder. Treatment consists of enzyme replacement therapy by the administration of recombinant GCR produced in Chinese hamster ovary cells. The production of anti-GCR antibodies has already been described with placenta-derived human GCR that requires successive chromatographic procedures. Here, we report a practical and efficient method to obtain anti-GCR polyclonal antibodies against recombinant GCR produced in Escherichia coli and further purified by a single step through nickel affinity chromatography. The purified GCR was used to immunize BALB/c mice and the induction of anti-GCR antibodies was evaluated by enzyme-linked immunosorbent assay. The specificity of the antiserum was also evaluated by western blot analysis against recombinant GCR produced by COS-7 cells or against endogenous GCR of human cell lines. GCR was strongly recognized by the produced antibodies, either as cell-associated or as secreted forms. The detected molecular masses of 59–66 kDa are in accordance to the expected size for glycosylated GCR. The GCR produced in E. coli would facilitate the production of polyclonal (shown here) and monoclonal antibodies and their use in the characterization of new biosimilar recombinant GCRs coming in the near future.
- Erickson, A. H., Ginns, E. I., & Barranger, J. A. (1985). Biosynthesis of the lysosomal enzyme glucocerebrosidase. Journal of biological chemistry, 260, 14319–14324.
- Ginns, E. I., Choudary, P. V., Tsuji, S., Martin, B., Stubblefield, B., Sawyer, J., et al. (1985). Gene mapping and leader polypeptide sequence of human glucocerebrosidase: Implications for Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America, 82, 7101–7105. CrossRef
- Aerts, J. M., Donker-Koopman, W. E., van der Vliet, M. K., Jonsson, L. M., Ginns, E. I., Murray, G. J., et al. (1985). The occurrence of two immunologically distinguishable beta-glucocerebrosidases in human spleen. European Journal of Biochemistry, 150, 565–574. CrossRef
- Beutler, E. (1992). Gaucher disease: New molecular approaches to diagnosis and treatment. Science, 256, 794–799. CrossRef
- Brady, R. O., & Barton, N. W. (1996). Enzyme replacement and gene therapy for Gaucher’s disease. Lipids, 31 Suppl, S137–S139. CrossRef
- Grabowski, G. A. (2008). Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet, 372, 1263–1271. CrossRef
- Zimran, A., Ilan, Y., & Elstein, D. (2009). Enzyme replacement therapy for mild patients with Gaucher disease. American Journal of Hematology, 84, 202–204. CrossRef
- Grabowski, G. A. (2004). Gaucher disease: Lessons from a decade of therapy. Journal of Pediatrics, 144, S15–S19. CrossRef
- Grace, M. E., Newman, K. M., Scheinker, V., Berg-Fussman, A., & Grabowski, G. A. (1994). Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression. Journal of biological chemistry, 269, 2283–2291.
- Jmoudiak, M., & Futerman, A. H. (2005). Gaucher disease: Pathological mechanisms and modern management. British Journal Haematology, 129, 178–188. CrossRef
- Fabbro, D., Desnick, R. J., & Grabowski, G. A. (1987). Gaucher disease: Genetic heterogeneity within and among the subtypes detected by immunoblotting. American Journal of Human Genetics, 40, 15–31.
- Germain, D. P. (2004). Gaucher’s disease: A paradigm for interventional genetics. Clinical Genetics, 65, 77–86. CrossRef
- Grabowski, G. A., Dinur, T., Osiecki, K. M., Kruse, J. R., Legler, G., & Gatt, S. (1985). Gaucher disease types 1, 2, and 3: Differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine. American Journal of Human Genetics, 37, 499–510.
- Kacher, Y., Brumshtein, B., Boldin-Adamsky, S., Toker, L., Shainskaya, A., Silman, I., et al. (2008). Acid beta-glucosidase: Insights from structural analysis and relevance to Gaucher disease therapy. Biological Chemistry, 389, 1361–1369. CrossRef
- Barranger, J. A., & O’Rourke, E. (2001). Lessons learned from the development of enzyme therapy for Gaucher disease. Journal of Inherited Metabolic Disease, 24(Suppl 2), 89–96. (discussion 87–88). CrossRef
- Xu, Y. H., Sun, Y., Barnes, S., & Grabowski, G. A. (2010). Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model. PLoS One, 5, e10750. CrossRef
- Brumshtein, B., Salinas, P., Peterson, B., Chan, V., Silman, I., Sussman, J. L., et al. (2010). Characterization of gene-activated human acid-beta-glucosidase: Crystal structure, glycan composition, and internalization into macrophages. Glycobiology, 20, 24–32. CrossRef
- Shaaltiel, Y., Bartfeld, D., Hashmueli, S., Baum, G., Brill-Almon, E., Galili, G., et al. (2007). Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher’s disease using a plant cell system. Plant Biotechnology Journal, 5, 579–590. CrossRef
- Aviezer, D., Brill-Almon, E., Shaaltiel, Y., Hashmueli, S., Bartfeld, D., Mizrachi, S., et al. (2009). A plant-derived recombinant human glucocerebrosidase enzyme—a preclinical and phase I investigation. PLoS One, 4, e4792. CrossRef
- Sinclair, G., Pfeifer, T. A., Grigliatti, T. A., & Choy, F. Y. (2006). Secretion of human glucocerebrosidase from stable transformed insect cells using native signal sequences. Biochemistry and Cell Biology, 84, 148–156. CrossRef
- Leonova, T., & Grabowski, G. A. (2000). Fate and sorting of acid beta-glucosidase in transgenic mammalian cells. Molecular Genetics and Metabolism, 70, 281–294. CrossRef
- Fabrega, S., Durand, P., Codogno, P., Bauvy, C., Delomenie, C., Henrissat, B., et al. (2000). Human glucocerebrosidase: Heterologous expression of active site mutants in murine null cells. Glycobiology, 10, 1217–1224. CrossRef
- Pasmanik-Chor, M., Elroy-Stein, O., Aerts, H., Agmon, V., Gatt, S., & Horowitz, M. (1996). Overexpression of human glucocerebrosidase containing different-sized leaders. Biochemical Journal, 317(Pt 1), 81–88.
- Ginns, E. I., Brady, R. O., Pirruccello, S., Moore, C., Sorrell, S., Furbish, F. S., et al. (1982). Mutations of glucocerebrosidase: Discrimination of neurologic and non-neurologic phenotypes of Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America, 79, 5607–5610. CrossRef
- Ginns, E. I., Tegelaers, F. P., Barneveld, R., Galjaard, H., Reuser, A. J., Brady, R. O., et al. (1983). Determination of Gaucher’s disease phenotypes with monoclonal antibody. Clinica Chimica Acta, 131, 283–287. CrossRef
- Aerts, J. M., Donker-Koopman, W. E., van Laar, C., Brul, S., Murray, G. J., Wenger, D. A., et al. (1987). Relationship between the two immunologically distinguishable forms of glucocerebrosidase in tissue extracts. European Journal of Biochemistry, 163, 583–589. CrossRef
- Bergmann, J. E., & Grabowski, G. A. (1989). Posttranslational processing of human lysosomal acid beta-glucosidase: A continuum of defects in Gaucher disease type 1 and type 2 fibroblasts. American Journal of Human Genetics, 44, 741–750.
- Beutler, E., & Kuhl, W. (1986). Glucocerebrosidase processing in normal fibroblasts and in fibroblasts from patients with type I, type II, and type III Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America, 83, 7472–7474. CrossRef
- Jonsson, L. M., Murray, G. J., Sorrell, S. H., Strijland, A., Aerts, J. F., Ginns, E. I., et al. (1987). Biosynthesis and maturation of glucocerebrosidase in Gaucher fibroblasts. European Journal of Biochemistry, 164, 171–179. CrossRef
- Barneveld, R. A., Tegelaers, F. P., Ginns, E. I., Visser, P., Laanen, E. A., Brady, R. O., et al. (1983). Monoclonal antibodies against human beta-glucocerebrosidase. European Journal of Biochemistry, 134, 585–589. CrossRef
- Beutler, E., Kuhl, W., & Sorge, J. (1984). Cross-reacting material in Gaucher disease fibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 81, 6506–6510. CrossRef
- Furbish, F. S., Blair, H. E., Shiloach, J., Pentchev, P. G., & Brady, R. O. (1977). Enzyme replacement therapy in Gaucher’s disease: Large-scale purification of glucocerebrosidase suitable for human administration. Proceedings of the National Academy of Sciences of the United States of America, 74, 3560–3563. CrossRef
- Sanger, F., Nicklen, S., & Coulson, A. R. (1977). DNA sequencing with chain-terminating inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 74, 5463–5467. CrossRef
- Ramos, C. R., Abreu, P. A., Nascimento, A. L., & Ho, P. L. (2004). A high-copy T7 Escherichia coli expression vector for the production of recombinant proteins with a minimal N-terminal His-tagged fusion peptide. Brazilian Journal of Medical and Biological Research, 37, 1103–1109. CrossRef
- Kaufman, R. J., Davies, M. V., Wasley, L. C., & Michnick, D. (1991). Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus. Nucleic Acids Research, 19, 4485–4490. CrossRef
- Berg-Fussman, A., Grace, M. E., Ioannou, Y., & Grabowski, G. A. (1993). Human acid beta-glucosidase. N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity. Journal of biological chemistry, 268, 14861–14866.
- Nelson, P. N., Reynolds, G. M., Waldron, E. E., Ward, E., Giannopoulos, K., & Murray, P. G. (2000). Monoclonal antibodies. Molecular Pathology, 53, 111–117. CrossRef
- Leenaars, M., & Hendriksen, C. F. (2005). Critical steps in the production of polyclonal and monoclonal antibodies: Evaluation and recommendations. ILAR Journal, 46, 269–279.
- Van Weely, S., Aerts, J. M., Van Leeuwen, M. B., Heikoop, J. C., Donker-Koopman, W. E., Barranger, J. A., et al. (1990). Function of oligosaccharide modification in glucocerebrosidase, a membrane-associated lysosomal hydrolase. European Journal of Biochemistry, 191, 669–677. CrossRef
- Generation of Polyclonal Antibodies Against Recombinant Human Glucocerebrosidase Produced in Escherichia coli
Volume 46, Issue 3 , pp 279-286
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press Inc
- Additional Links
- Polyclonal antibody
- Gaucher’s disease
- Recombinant protein expression
- Lysosomal storage disorder
- Industry Sectors
- Author Affiliations
- 1. Centro de Biotecnologia, Instituto Butantan, Av. Vital Brasil, 1500, São Paulo, SP, 05503-900, Brazil
- 2. Interunidades em Biotecnologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil
- 3. Laboratório de Imunopatologia, Instituto Butantan, Av. Vital Brasil, 1500, 05503-900, São Paulo, SP, Brazil
- 4. Centro de Biotecnologia, Instituto de Pesquisas Energéticas e Nucleares, São Paulo, SP, Brazil